NCT05725018 - A Phase 3b Study for the Treatment of Dystrophic Epidermolysis Bullosa (DEB) in New and Previously EB-101 Treated Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 2, 2023

Primary Completion Date

September 30, 2025

Study Completion Date

September 30, 2025

Conditions

Epidermolysis BullosaRecessive Dystrophic Epidermolysis BullosaRDEB

Interventions

BIOLOGICAL

EB-101 Surgical application of RDEB wounds

"EB-101 autologous RDEB keratinocytes isolated from skin biopsies and transduced with a recombinant retrovirus containing a full-length COL7A1 expression cassette for C7~Other Names:~• LZRSE-Col7A1 Engineered Autologous Epidermal Sheets \[LEAES\]"

Trial Locations (2)

94063

Stanford University, Redwood City

01605

University of Massachusetts Medical School, Worcester